Labetalol
| 證據等級: L5 | 預測適應症: 4 個 |
目錄
Labetalol: From Hypertension to Malignant Renovascular Hypertension
One-Sentence Summary
Labetalol is a combined alpha-1/non-selective beta-adrenergic blocker, a drug class established for treating hypertension, including hypertensive emergencies. The TxGNN model predicts it may be effective for Malignant Renovascular Hypertension, with no clinical trials and 2 case-report publications currently supporting this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Hypertension (based on known pharmacology; no formal Taiwan license text available — drug not marketed in Taiwan) |
| Predicted New Indication | Malignant Renovascular Hypertension |
| TxGNN Prediction Score | 99.08% |
| Evidence Level | L4 |
| US Market Status | ✗ Not Marketed (Taiwan) |
| Number of NDAs | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the evidence pack. Based on known pharmacology, labetalol is a combined alpha-1 and non-selective beta-adrenergic receptor blocker, a drug class widely used for hypertension and, notably, as one of the standard intravenous agents for hypertensive emergencies. Its blood-pressure-lowering efficacy in general hypertension is well established.
Malignant renovascular hypertension is fundamentally a severe subtype of hypertension involving renal vasculature. Because the predicted indication shares the same underlying pathophysiology (systemic hypertension) as labetalol’s established use, the mechanistic link is a direct extension of an already-confirmed pharmacological action rather than a novel mechanism hypothesis — labetalol’s alpha/beta blockade lowers systemic blood pressure, which is the core therapeutic goal in malignant renovascular hypertension as well.
This mechanistic reasonableness is supported qualitatively rather than by high-tier clinical evidence: the only literature identified are two older case reports describing labetalol’s use in controlling malignant hypertension, not dedicated trials in the renovascular subtype.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 7242419 | 1981 | Case report | The Medical Journal of Australia | Case of malignant hypertension with renal arteritis/aneurysms; minoxidil plus labetalol used for initial blood pressure control |
| 15113447 | 2004 | Case report | BMC Nephrology | Hyponatremic hypertensive syndrome in an 18-month-old presenting as malignant (renovascular) hypertension |
US Market Information
Currently no marketing authorizations recorded (0 licenses; drug not marketed in Taiwan)
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: The mechanistic rationale is sound — labetalol is an established treatment for hypertensive emergencies and malignant hypertension broadly — but direct evidence specific to the renovascular subtype is limited to two decades-old case reports with no clinical trials, placing this at Evidence Level L4.
To proceed, the following is needed:
- TFDA label warnings/contraindications (currently a Blocking data gap — required before safety (S1) evaluation)
- Formal mechanism of action (MOA) documentation from DrugBank
- Taiwan market authorization status confirmation (currently unmarketed, 0 licenses)
- Dedicated clinical evidence in malignant renovascular hypertension, or at minimum contemporary case series, to move beyond L4
- Route compatibility and similarity-to-original-indication analysis (currently marked “pending” in the evidence pack)
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.